Athira Pharma logo

Athira Pharma

athira.com

Athira Pharma develops novel small molecule therapies for diseases with limited treatment options, including metastatic breast cancer and ALS. Its lead drug candidates are lasofoxifene and brelgometon (ATH-1105), which are evaluated in clinical trials to improve care for patients through innovative research and product development.

Facts

HQ
Seattle
Sectors
Biopharmaceuticals, Biotech, Pharmaceuticals
Employees
30
Stage
Series B

Is this your organization? Claim it

EIT Pharma, led by ex-Athira CEO Leen Kawas, raises $35M Series A to advance lonafarnib for chronic hepatitis D

Kirkland-based EIT Pharma, led by former Athira CEO Leen Kawas, raised $35 million in an oversubscribed Series A led by Propel Bio Partners to support FDA review, manufacturing and commercial preparations for lonafarnib as an oral treatment candidate for chronic hepatitis D. The FDA accepted EIT Pharma's New Drug Application for lonafarnib on Aug. 11; the drug was acquired from Eiger BioPharmaceuticals' 2024 bankruptcy sale.

Leen Kawas returns as CEO of Kirkland’s EIT Pharma after 2021 Athira exit, to advance lonafarnib

Leen Kawas has returned to operations as CEO of Kirkland-based EIT Pharma after leaving Athira in 2021 and running Propel Bio Partners with investor Richard Kayne; she will lead the small infectious-disease biotech as it advances its lead drug lonafarnib toward data readouts while balancing travel and investment work. The company has about a dozen employees, occupies a coworking space in Kirkland, and expects to need new Seattle-area office space within a year.

See all 40 news stories about Athira Pharma.

People

  • Rachel Lenington Executive, Chief Operating Officer and Chief Development Officer

Online